跳至主要内容
临床试验/NCT07305350
NCT07305350进行中(未招募)2 期

EFFICACY OF MELATONIN IN MANAGEMENT OF HYPOXIC ISCHEMIC ENCEPHALOPATHY (HIE) IN NEONATES

University of Child Health Sciences and Children's Hospital, Lahore1 个研究点 分布在 1 个国家目标入组 110 人开始时间: 2025年12月10日最近更新:
干预措施

试验速览

阶段
2 期
状态
进行中(未招募)
发起方
入组人数
110
试验地点
1
主要终点
Neonate survival rate

研究概览

简要总结

To compare the survival rate and improvement in stage of hypoxic ischemic encephalopathy (HIE) at day 7 of treatment in neonates treated with versus without melatonin in addition to standard supportive therapy.

详细描述

This is a randomized control trial and the purpose of this study is to determine efficacy of melatonin in management of hypoxic ischemic encephalopathy in newborns. Baseline characteristics will be documented after which patients will be divided into two groups by paper lottery method namely group A in which newborns will be given single 10mg dose of melatonin through nasogastric tube in addition to standard supportive therapy and group B in which patients will be given standard supportive therapy only.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
1 Hour 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Group A

Experimental

55 neonates will be assigned group A in which newborns will be given single 10mg dose of melatonin through nasogastric tube in addition to standard supportive therapy.

干预措施: Melatonin (Drug)

Group B

Active Comparator

55 neonates will be assigned group B in which patients will be given standard supportive therapy only. Standard supportive therapy included oxygen therapy, intravenous (IV) fluids, intensive monitoring, broad-spectrum antibiotic cover for possible role of infection

干预措施: intravenous (IV) fluids, intensive monitoring, broad-spectrum antibiotic cover (Combination Product)

结局指标

主要结局

Neonate survival rate

时间窗: 28 days of life

Role of melatonin will be determined primarily by survival rate in neonates with hypoxic ischemic encephalopathy at 28 days of life.

次要结局

  • Improvement in stage of HIE(Day 1, 3 and 7 of life)

研究者

发起方
University of Child Health Sciences and Children's Hospital, Lahore
申办方类型
Other
责任方
Principal Investigator
主要研究者

Dr. Amina Cheema

Dr Amina Cheema

University of Child Health Sciences and Children's Hospital, Lahore

研究点 (1)

Loading locations...

相似试验